Objective.:To determine the ability of patients to be treated with biweekly bevacizumab and weekly taxane chemotherapy in women with advanced,refractory ovarian cancer. Methods.:Ten patients with advanced,recurrent,an...Objective.:To determine the ability of patients to be treated with biweekly bevacizumab and weekly taxane chemotherapy in women with advanced,refractory ovarian cancer. Methods.:Ten patients with advanced,recurrent,and refractory ovarian cancer who were treated with biweekly bevacizumab (10 mg/kg) and weekly taxane (paclitaxel or docetaxel) chemotherapy days 1,8,15,and 22 every 28 days were identified retrospectively. All patients were followed with serial CA125 measurements prior to each cycle of therapy; cross-sectional imaging was not used to follow response to therapy. Toxicities were assessed prior to each cycle of treatment. Results.:Of the 10 patients treated with weekly taxane and biweekly bevacizumab therapy,all 9 that were evaluable had a decrease in CA125. Five patients have had an increase in CA125 after therapy after a median of three cycles (range 1-4),while 3 patients experienced normalization of CA125 and another with continued improvement in CA125. All symptomatic patients experienced rapid palliation of pain,nausea,and ascites. Side effects have been mild,with no grade 3 or 4 toxicities noted. No treatment delays or discontinuations have been necessary. Conclusion.:Treatment of advanced,recurrent,refractory epithelial ovarian cancer with bevacizumab and weekly taxane chemotherapy leads to significant,albeit temporary,improvement in the cancer-related symptoms in women treated on this regimen,and short-term exposure to these agents is not associated with significant toxicity. Thus,continued investigation of bevacizumab with weekly scheduling of cytotoxic chemo- therapy is imperative.展开更多
文摘Objective.:To determine the ability of patients to be treated with biweekly bevacizumab and weekly taxane chemotherapy in women with advanced,refractory ovarian cancer. Methods.:Ten patients with advanced,recurrent,and refractory ovarian cancer who were treated with biweekly bevacizumab (10 mg/kg) and weekly taxane (paclitaxel or docetaxel) chemotherapy days 1,8,15,and 22 every 28 days were identified retrospectively. All patients were followed with serial CA125 measurements prior to each cycle of therapy; cross-sectional imaging was not used to follow response to therapy. Toxicities were assessed prior to each cycle of treatment. Results.:Of the 10 patients treated with weekly taxane and biweekly bevacizumab therapy,all 9 that were evaluable had a decrease in CA125. Five patients have had an increase in CA125 after therapy after a median of three cycles (range 1-4),while 3 patients experienced normalization of CA125 and another with continued improvement in CA125. All symptomatic patients experienced rapid palliation of pain,nausea,and ascites. Side effects have been mild,with no grade 3 or 4 toxicities noted. No treatment delays or discontinuations have been necessary. Conclusion.:Treatment of advanced,recurrent,refractory epithelial ovarian cancer with bevacizumab and weekly taxane chemotherapy leads to significant,albeit temporary,improvement in the cancer-related symptoms in women treated on this regimen,and short-term exposure to these agents is not associated with significant toxicity. Thus,continued investigation of bevacizumab with weekly scheduling of cytotoxic chemo- therapy is imperative.
